Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

NIH 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Tumor-Agnostic 1Thoracic 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 15Lymphoma 14Lymphoma, T-Cell, Cutaneous 12Lymphoma, T-Cell 12Lymphoma, Large B-Cell, Diffuse 6Leukemia, Lymphocytic, Chronic, B-Cell 6Lymphoma, Large-Cell, Anaplastic 5Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Prostatic Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 3Pancreatic Neoplasms 3Neoplasms 3Mycosis Fungoides 3Multiple Myeloma 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Follicular 3Lung Neoplasms 3Hodgkin Disease 3Hematologic Neoplasms 3Congenital Abnormalities 3Colorectal Neoplasms 3Carcinoma, Renal Cell 3Burkitt Lymphoma 3Waldenstrom Macroglobulinemia 2Thyroid Neoplasms 2Small Cell Lung Carcinoma 2Sezary Syndrome 2

Interventions

Gemcitabine 109Paclitaxel 92Carboplatin 79pembrolizumab 75Bevacizumab 75Surveys and Questionnaires 70Docetaxel 69Cisplatin 67Nivolumab 48Exercise 48Capecitabine 48Cyclophosphamide 47Sorafenib 43Fluorouracil 43Irinotecan 42Pemetrexed 37Albumin-Bound Paclitaxel 35Radiotherapy 34Dexamethasone 34Blood Specimen Collection 34Oxaliplatin 31Leucovorin 31Erlotinib Hydrochloride 31trametinib 30130-nm albumin-bound paclitaxel 29Cetuximab 28Therapeutics 26Ipilimumab 26Standard of Care 25Methods 25

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Neoplasms × romidepsin × Clear all
NCT00020202 2024-03-04

FR901228 in Treating Patients With Refractory or Progressive Small Cell Lung Cancer or Non-small Cell Lung Cancer

National Cancer Institute (NCI)

Phase 2 Completed
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Genetic Diseases, Inborn, Small Cell Lung Carcinoma

NCT00048334 2019-12-12

Depsipeptide to Treat Thyroid and Other Advanced Cancers

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
28 enrolled
Tumor-Agnostic

Neoplasms

NCT01353664 2019-11-25

A Rollover Study for Patients Who Participated in Other Romidepsin Protocols

Celgene

Phase 2 Completed
19 enrolled 12 charts
Lymphoid

Lymphoma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡